Neo GenesisNeo Genesis🃏All Ledyba cards
Ask about Ledyba
Ledyba #63 Pokémon card from Neo Genesis

Ledyba 63/111

Neo Genesis

👁 Watch📊 Add to portfolioFree — no card required to register.
Find this card on eBay

Affiliate link · we may earn commission

Ledyba #63 from Neo Genesis currently trades at $1.61 raw, with PSA 10 copies reaching $140.50 — a 87.3x grade premium.
Current Prices (USD)
Ungraded
$1.61
PSA 7
$6.33
PSA 8
$6.33
PSA 9
$10.75
PSA 10
$140.50
ACE 10
BGS 10 Black
$915.00
CGC 10 Pristine
$19.00
Compare on eBay

Affiliate link · we may earn commission

Quick price facts

Ledyba 63/111 from Neo Genesis has a current raw market value of $1.61.

Current raw value
$1.61
PSA 9 value
$10.75
PSA 10 value
$141
PSA 10 premium vs raw
87.3× raw
View all cards from Neo Genesis
Collector Intel
87.3x
Raw → PSA 10
High-risk grade
6.7x
Raw → PSA 9
Grade multiplier

Calculated from price history, PSA population data, and market trends. Not financial advice.

Grading Calculator

Based on PSA Standard tier (~$25 USD). Assumes a perfect PSA 10 result — actual outcome depends on card condition.

⚠️ High-variance grade. PSA 10 is 87x the raw price. The expected value accounts for the realistic probability.
$2
Buy Raw
~$25
Grading Fee
PSA Standard
$141
PSA 10 Value
+$114
Best Case (PSA 10)
if you pull a 10
Grade Multiples vs Raw
PSA 9$116.7x raw
PSA 10$14187.3x raw

Frequently asked questions

How much is Ledyba #63 from Neo Genesis worth?+
Ledyba #63 from Neo Genesis is currently worth Raw: $1.61, PSA 9: $10.75, PSA 10: $141 based on recent sold listings. Prices update daily from real eBay sales.
Is Ledyba #63 worth grading?+
The PSA 10 price of $141 is 87.3× the raw price of $1.61. After a ~$25 grading fee, a PSA 10 result would net approximately $139 — assuming the card grades a 10.
Where do PokePrices Ledyba #63 prices come from?+
Prices are tracked nightly from real sold listings on PriceCharting (raw, PSA 9 and PSA 10). PSA population data is sourced from PSA's public reports. We do not use asking prices — only confirmed sales.